Albany, NY -- (SBWIRE) -- 02/02/2017 -- Global Anticonvulsants for Neuropathic Pain Market

Neurapthic pain (NP) is a severe pain associated with a number of diseases such as cancer, diabetes, and herpes zoster. This pain affects almost 1% of the world’s total population and is aggravated as a result of dysfunction, lesion, or transitory perturbation in the peripheral and central nervous system. Some other causes of neuropathic pain include trigeminal neuralgia, peripheral and entrapment neuropathy, brachial plexus avulsion pain, spinal cord injury pain, post-herpetic neuralgia, arachnoiditis, phantom limb pain, and post-stroke pain.

The report presents a definitive analysis of market drivers, market restraints, and trends that will impact progression of the global anticonvulsants for neuropathic pain market until the end of 2025. The report charts the developmental growth map in the future by analyzing the past performance of the market.

Request a Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=32

The research report analyzes the global anticonvulsants for neuropathic pain market from a competitive viewpoint as well. The report finds out how innovations and product development will present growth opportunities to market players to serve niche patient areas. The analysis of changing competitive hierarchy is presented through graphs and pictorial representations. The report is compiled after collecting data from industry-centric databases and scrutinized using validated analytical tools.

Global Anticonvulsants for Neuropathic Pain Market: Drivers and Restraints

The increasing incidence of people with neuropathic pain is one of the major factors driving the anticonvulsants for neuropathic pain market. In addition, a high number of patients refractory to alternate treatment methods, increasing use of generic drugs compared to branded drugs, and a high rate of polypharmacy are some other factors driving the growth of this market.

The development of novel drug molecules for neuropathic drug indications is also propelling the growth of this market. This is because less than 50% of the patients respond to existing drugs that are available for neuropathic drug indications. Moreover, these drugs are associated with a number of side effects, particularly when administered systemically. Hence, new drug variants that can provide convincing action mechanism will be a game changer in the global neuropathic pain market.

Request for TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=32

Some of the newer anticonvulsant drugs for neuropathic pain include Depomed’s Gralise (gabapentin gastric-retention), which is available since 2011 and is a ‘once â€"daily’ formulation. XenoPort’s Horizant (gabapentin encarbil) was introduced in 2012 and is a “twice-daily’ formulation.

Global Anticonvulsants for Neuropathic Pain Market: Advantages of Anticonvulsants

Neuropathic pain can be managed by opioids such as morphine, non-steroidal anti-inflammatory drugs, and anticonvulsant drugs. Anticonvulsants are normally used to control epileptic seizures but may also be used for treating neuropathic pain conditions such as fibromyalgia and postherpetic neuralgia. Anticonvulsants impede seizures through multiple mechanisms such as:

Functional obstruction of voltage-gated-calcium channels
Impediment of glutamergic neurotransmission
Functional obstruction of voltage-sodium channels
Direct or indirect enhancement of hindering GABAergic neurotransmission
Companies Mentioned in report

Read Complete Report @ https://www.tmrresearch.com/anticonvulsants-for-neuropathic-pain-market

The report provides a detailed vendor landscape of the global anticonvulsants for neuropathic pain market with a business profile of major companies that operate in this market. These are Teva Pharmaceuticals, Depomed Inc., Janssen Pharmaceutical Inc., Cephalon Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AbbVie Inc., and XenoPort Inc.